SCHEMBL570868

SCHEMBL570868

COC(=O)CN(C)S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
MAPK1 P28482 1/20 0.60
GAA P10253 2/20 0.58
LMNA P02545 2/20 0.57
KDM4E B2RXH2 1/20 0.57
HSD17B10 Q99714 1/20 0.57
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TSHR P16473 1/20 0.53
MCOLN3 Q8TDD5 1/20 0.53
CYP3A4 P08684 1/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
ALDH1A1 P00352 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HIF1A Q16665 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673729 0.86 ALDH1A1 (0.56) KMT2AMAPK1GAALMNAKDM4E
SCHEMBL11580067 0.86 GAA (0.58) KMT2AGAARAB9AMCOLN3CYP3A4
SCHEMBL19900168 0.86 ALDH1A1 (0.58) KMT2AMAPK1LMNAKDM4ERAB9A
SCHEMBL11575496 0.85 TSHR (0.54) KMT2AMAPK1LMNAKDM4EHSD17B10
SCHEMBL12115465 0.84 KMT2A (0.47) KMT2AMAPK1GAALMNAKDM4E
SCHEMBL15705805 0.83 MMP1 (0.51) KMT2AMAPK1LMNAKDM4EMEN1
SCHEMBL6093390 0.83 MMP9 (0.46) KMT2AMAPK1GAAKDM4ERAB9A
SCHEMBL11550968 0.83 TSHR (0.52) KMT2AMAPK1LMNAHSD17B10SMN1; SMN2
SCHEMBL15705781 0.82 KMT2A (0.52) KMT2AMAPK1GAALMNAKDM4E
SCHEMBL15705731 0.82 GAA (0.54) KMT2AGAARAB9AMCOLN3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954258-B2 STAT3 dimerization inhibitors H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2021-03-23 US disclosed
CN-110305143-B Furan [2,3-c ] pyridine derivative and preparation method and application thereof 济南新科医药科技有限公司 2021-03-09 CN disclosed
US-20200199160-A1 STAT3 DIMERIZATION INHIBITORS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2020-06-25 US disclosed
US-20190382422-A1 SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-12-19 US disclosed
US-10377780-B2 Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-08-13 US disclosed
US-10377780-B2 Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-08-13 US disclosed
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-02-05 US disclosed
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-02-05 US disclosed
US-20180179235-A1 STAT3 DIMERIZATION INHIBITORS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2018-06-28 US disclosed
US-9822135-B2 STAT3 dimerization inhibitors H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2017-11-21 US disclosed
US-20130225621-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN UNIVERSITY OF TORONTO MISSISSAUGA (CA) 2013-08-29 US disclosed
US-20130225621-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN UNIVERSITY OF TORONTO MISSISSAUGA (CA) 2013-08-29 US disclosed
EP-2600860-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS University of Central Florida Research Foundation, Inc. (US) 2013-06-12 EP disclosed
WO-2012018868-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-02-09 WO disclosed
WO-2012018868-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-02-09 WO disclosed
US-7166580-B2 Compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2007-01-23 US disclosed
US-20030166575-A1 Compounds which inhibit leukocyte adhesion mediated by VLA-4 BIOGEN MA INC. 2003-09-04 US disclosed
US-6559127-B1 Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses ATHENA NEUROSCIENCES, INC. 2003-05-06 US disclosed
EP-1001973-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2000-05-24 EP disclosed
WO-1999006433-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190382422-A1 SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF STAT3, STAT5A, STAT6 KMT2A 2502/4885MAPK1 740/4885GAA 2232/4885
US-20200199160-A1 STAT3 DIMERIZATION INHIBITORS STAT3, JAK2, STAT1 KMT2A 2581/4885MAPK1 1739/4885GAA 3154/4885
US-20180179235-A1 STAT3 DIMERIZATION INHIBITORS STAT3, JAK2, STAT1 KMT2A 2581/4885MAPK1 1739/4885GAA 3154/4885
US-10954258-B2 STAT3 dimerization inhibitors STAT3, JAK2, STAT1 KMT2A 2581/4885MAPK1 1739/4885GAA 3154/4885
US-10377780-B2 Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof STAT3, STAT5A, STAT6 KMT2A 2502/4885MAPK1 740/4885GAA 2232/4885
US-20130225621-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN STAT3, STAT1, STAT4 KMT2A 1961/4885MAPK1 426/4885GAA 949/4885
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein STAT3, STAT1, STAT4 KMT2A 1961/4885MAPK1 426/4885GAA 949/4885
US-20030166575-A1 Compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, CD4 KMT2A 1871/4885MAPK1 1402/4885GAA 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.